rosiglitazone has been researched along with exenatide in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 13 (92.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Washburn, WN | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C | 1 |
| Al-Jebawi, AF | 1 |
| Heller, C; Kühn, MC; Mülders-Opgenoorth, B; Scherbaum, WA; Schinner, S; Schott, M; Willenberg, HS | 1 |
| Nauck, MA | 1 |
| Bøgelund, M; Ericsson, Å; Jendle, J; Nilsen, B; Ridderstråle, M; Torffvit, O | 1 |
| Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME | 1 |
| Azeloglu, EU; Badimon, JJ; Benard, L; Chen, Y; Giannarelli, C; Goldfarb, J; Gottesman, O; Hajjar, RJ; Iyengar, R; Nishimura, T; Zafar, MU; Zhao, S | 1 |
| Hao, M; Hu, YR; Kuang, HY; Xiao, YC; Zheng, JX | 1 |
| Soni, H | 1 |
| Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
| Chen, SH; Liu, XN; Peng, Y; Sun, QY | 1 |
| Blazina, I; Selph, S | 1 |
6 review(s) available for rosiglitazone and exenatide
| Article | Year |
|---|---|
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin | 2019 |
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone | 2019 |
2 trial(s) available for rosiglitazone and exenatide
| Article | Year |
|---|---|
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Venoms; Weight Gain | 2010 |
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Receptors, Glucagon; Rosiglitazone; Thiazolidinediones; Venoms | 2012 |
6 other study(ies) available for rosiglitazone and exenatide
| Article | Year |
|---|---|
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Remission Induction; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2010 |
Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation.
Topics: Animals; Cell Proliferation; Cells, Cultured; Drug Evaluation, Preclinical; Exenatide; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Mice; Mice, Inbred C57BL; Peptides; Receptors, Glucagon; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Tolbutamide; Up-Regulation; Venoms; Wnt4 Protein | 2011 |
Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
Topics: Cost of Illness; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Disease Management; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Peptides; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2012 |
Systems pharmacology of adverse event mitigation by drug combinations.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Blood Coagulation; Confounding Factors, Epidemiologic; Databases as Topic; Diabetes Mellitus, Experimental; Drug Combinations; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Exenatide; Heart Function Tests; Humans; Mice; Myocardial Infarction; Peptides; Plasminogen Activator Inhibitor 1; Rosiglitazone; Systems Biology; Thiazolidinediones; Thrombelastography; Ultrasonography; United States; United States Food and Drug Administration; Venoms | 2013 |
Exendin-4 shows no effects on the prostatic index in high-fat-diet-fed rat with benign prostatic hyperplasia by improving insulin resistance.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Exenatide; Glucagon-Like Peptide-1 Receptor; Insulin Resistance; Male; Peptides; Prostate; Prostatic Hyperplasia; Rats; Rats, Wistar; Receptors, Glucagon; Rosiglitazone; Severity of Illness Index; Thiazolidinediones; Venoms | 2015 |
Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity.
Topics: Animals; Clinical Trials as Topic; Diabetes Complications; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Mice; Mice, Obese; Obesity; Oxyntomodulin; Peptides; Rats; Receptors, Glucagon; Recombinant Proteins; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Venoms | 2016 |